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Insulin-Independent Reversal of Type-1 Diabetes 
Following Transplantation of Adult Brown 
Adipose Tissue Supplemented With IGF-1
Subhadra C. Gunawardana, PhD1 and David W. Piston, PhD1
Type 1 diabetes (T1D) is a serious autoimmune disease requiring constant glucose management. T1D affects 
about 2 million Americans and an estimated 21 million peo-
ple worldwide, with 40 000 new cases diagnosed each year. 
Traditional therapy involves insulin replacement, either 
directly or via islet/pancreas transplantation. Besides incon-
venience, exogenous insulin administration carries the risk 
of hypoglycemia unawareness, a potentially fatal outcome. 
Pancreas transplantation involves the obvious limitations of 
invasive surgery and life-long immuno-suppression, while islet 
transplantation is also limited by availability of donor tissue, 
need for immuno-suppression, and return to insulin depend-
ence over the long term.1-5 Despite continuous refinement 
through the past decades, effective solutions for these basic 
limitations have not been found. A comprehensive review 
of the safety and efficacy of commonly used type 2 diabetes 
drugs as add-on therapies to insulin in T1D concluded that 
their efficacy was minimal or modest, and such add-on ther-
apy was not generally recommended for T1D.6 Thus, there is 
an ongoing need for better therapies for T1D.
The ultimate goal in treating T1D is to restore glucose 
homeostasis. Our work has shown that glucose homeosta-
sis can be achieved without insulin, using subcutaneously 
placed embryonic brown adipose tissue (BAT) transplants.7,8 
In both streptozotocin-diabetic and autoimmune-induced 
nonobese diabetic (NOD) mice, BAT transplants reestablish 
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Basic Science
Background. As our previous publications show, it is feasible to reverse type 1 diabetes (T1D) without insulin in multiple 
mouse models, through transplantation of embryonic brown adipose tissue (BAT) in the subcutaneous space. Embryonic 
BAT transplants result in rapid and long-lasting euglycemia accompanied by decreased inflammation and regenerated 
healthy white adipose tissue, with no detectable increase in insulin. To translate this approach to human patients, it is neces-
sary to establish practical alternatives for embryonic tissue. Adult adipose tissue transplants or BAT-derived stem cell lines 
alone fail to reverse T1D. A likely reason is transplant failure resulting from lack of growth factors abundant in embryonic 
tissue. Adding growth factors may enable transplants to survive and vascularize as well as stimulate adipogenesis and 
decrease inflammation in the surrounding host tissue. Previous data points to insulin like growth factor 1 (IGF-1) as the most 
likely candidate. Embryonic BAT abundantly expresses IGF-1, and embryonic BAT transplant recipients exhibit increased 
plasma levels of IGF-1. Therefore, we tested the ability of temporary administration of exogenous IGF-1 to enable adult BAT 
transplants to correct T1D. Methods. Fresh BAT from healthy adult CB7BL/6 donors were transplanted in the subcuta-
neous space of hyperglycemic nonobese diabetic recipients. Exogenous IGF-1 was administered daily for a week following 
transplant, at 100 µg/kg SC. Results. Adult BAT transplants with IGF-1 supplementation produced rapid long-lasting 
euglycemia at a 57% success rate, in contrast with no recovery in the control groups who received adult BAT alone, IGF-1 
alone, or no treatment. Conclusions. Temporary supplementation with IGF-1 enables adult BAT transplants to correct 
T1D phenotypes independent of insulin, providing a possible route to translate this treatment to human patients.
(Transplantation Direct 2019;5: e500; doi: 10.1097/TXD.0000000000000945. Published online 8 October, 2019.)
10.1097/TXD.0000000000000945
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normoglycemia independent of insulin. T1D is associated with 
inflammation both generalized and in white adipose tissue 
(WAT), and loss of WAT.9-11 Embryonic BAT transplants lead 
to remarkable recovery of WAT, decreased inflammation, and 
reversal of diabetes.7,8 Euglycemia correlates with suppression 
of glucagon, and progressive increases in plasma adiponectin, 
insulin like growth factor 1 (IGF-1), and sometimes leptin. 
Thus, it appears that a combination alternate hormones aris-
ing from BAT transplant and/or regenerated WAT establishes 
a new physiological equilibrium, compensating for endocrine 
pancreas.
While this technique is proven effective in long-term rever-
sal of T1D in mice, transplantation of embryonic tissue is 
not a practical solution for human patients. The goal of the 
current study was to implement appropriate modifications to 
reproduce the results with adult BAT transplants, a plausible 
alternative to embryonic BAT in clinical settings.
The presence of BAT in healthy human adults and its 
importance in combating metabolic disease is demonstrated 
in recent literature.12-14 While several studies show the ability 
of adult BAT and WAT transplants to alleviate diabetes and 
obesity, and to improve metabolism,13-19 complete reversal of 
insulin-dependent diabetes has not been achieved as it is with 
embryonic BAT transplants. According our own experience, 
transplantation of adult BAT or WAT alone fails to reverse 
T1D. Certain growth factors are abundant in embryonic tis-
sue, and may enable embryonic BAT transplants to survive 
and vascularize in the recipients’ subcutaneous space as well 
as stimulate adipogenesis and decrease inflammation in the 
surrounding host tissue. Plausible candidate growth factors 
include IGF-1, fibroblast growth factor 21, and adiponectin, 
all of which are highly expressed in embryonic tissue, possess 
adipogenic and anti-inflammatory properties, and can medi-
ate insulin-independent glucose transport and metabolism in 
peripheral tissues.20-40
Our data strongly point to donor-origin IGF-1 as a criti-
cal mediator in the early changes following BAT transplant.7,8 
Reversal of diabetes occurs only with donor embryonic BAT 
from healthy C57BL/6 mice, and not with donor BAT from 
NOD mice who are deficient of IGF-1. IGF-1 levels in recipi-
ents’ plasma significantly increase within a week of BAT 
transplant placement, and progressively increase thereaf-
ter parallel to weight gain and WAT regeneration, in nega-
tive correlation with proinflammatory cytokines.7,8 IGF-1 is 
abundantly expressed in freshly isolated BAT from C57BL/6 
embryos.7 Newly formed WAT in NOD transplant recipients 
continues to express IGF-1 for several months posttransplant, 
in contrast to little or no expression in control animals.7,8 It 
is noteworthy that only 50% of embryonic BAT transplants 
result in long-term euglycemia, and the ones that fail lack this 
increase of IGF-1 but instead show a progressive decrease of 
IGF-1.7 Thus, it seems that the presence of IGF-1 during the 
early stage of BAT transplant is critical for establishment of 
the new equilibrium of alternate hormones. Adipogenic and 
anti-inflammatory properties of IGF-1 might enable the regen-
eration of healthy WAT, which in turn could secrete other 
insulin-mimetic adipokines to compensate for the function of 
insulin. IGF-1 may also have direct actions on glucose lower-
ing through insulin-independent glucose uptake via GLUT1 
and GLUT3 transporters.34-36,40 Pharmacological inhibition 
of the insulin receptor in euglycemic BAT transplant recipi-
ents partially impairs their glucose tolerance,8 suggesting 
the occupation of insulin receptor by a noninsulin hormone. 
IGF-1 is a candidate here as well, due to the structural similar-
ity of insulin and IGF-1 receptors.41,42
Based on the aforementioned data, we hypothesize that the 
failure of adult BAT transplants to reverse T1D is due to the 
lack of IGF-1, which may be corrected by supplementation 
with exogenous IGF-1 during the early stages. To test this 
hypothesis, we performed experiments to determine whether 
adult BAT transplants temporarily supplemented with IGF-1 
can produce euglycemia in NOD mice with autoimmune-
induced diabetes.
MATERIALS AND METHODS
Experimental Design
All animal studies were approved by the Washington 
University Institutional Animal Care and Use Committee, 
under the Animal Welfare Assurance # A-3381-01, and 
Protocol # 20150121. BAT transplants were performed as 
described previously,7,8 on female NOD mice (Jackson labs, 
stock # 001976) 4–6 months old. Donor adipose tissue came 
from healthy young adult C57BL/6 females (Jackson labs, 
stock #000664) 1–2 months old. Experiments were per-
formed on NOD mice determined diabetic by a repeated non-
fasting blood glucose level over 200 mg/dL. The test group 
was provided with exogenous IGF-1 for the first 7 days fol-
lowing BAT transplant (100 µg/kg/day SC), in the lower end 
of the dosage range found in the literature on IGF-1 adminis-
tration to mice and rats for various purposes. Control groups 
included diabetic mice who received adult BAT transplants 
alone, IGF-1 injections alone, or saline injections alone. Body 
weight was recorded, and non-fasting blood samples were col-
lected before and at regular intervals after treatment, that is, 
every week for the first month following treatment, and every 
month thereafter. Metabolic parameters, such as blood glu-
cose, insulin, glucagon, adiponectin, and IGF-1, were meas-
ured from transplant and control groups at regular intervals. 
Glucose tolerance tests were performed on representative 
euglycemic transplant recipients in comparison with normal 
and diabetic controls. Depending on the group and glycemic 
status, mice were euthanized at different time points after 
1 month, and tissues were collected postmortem. The pres-
ence of insulin and glucagon in the pancreas, and the pres-
ence of insulin and IGF-1 in adipose tissue, were verified with 
immunofluorescence.
Isolation of Donor Tissue
Donor mice are anesthetized with ketamine/xylazine 
(200/40 mg/kg IP). Following aseptic preparation, interscapu-
lar adipose tissue is exposed through a dorsal midline skin 
incision. WAT is gently removed, and the BAT is dissected 
out. The mouse is immediately killed by cervical dislocation 
while under anesthesia. Freshly isolated BAT is placed in ster-
ile ice-cold HBSS, and transplanted into recipients as quickly 
as possible.
Transplantation
Freshly isolated adult BAT is transplanted in the subcutane-
ous space of diabetic recipients. Following general anesthesia 
and aseptic preparation, a small (2–4 mm) incision is made in 
the skin of the dorsal body surface caudal to the endogenous 
BAT. A subcutaneous pocket is made by blunt dissection using 
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a blunt-ended micro spatula. Donor tissue is introduced into 
the pocket with Dumont forceps and pushed in with blunt-
ended micro spatula. The incision is closed by gentle pressure 
with hemostats alone, or with 1–2 simple interrupted sutures 
as necessary with 5–0 nonabsorbable sutures. One to 2 lobes 
of adult BAT are introduced into each recipient. Surgeries are 
performed under general anesthesia with ketamine/xylazine 
(100/20 mg/kg) IP, and postoperative analgesia is provided 
with ketoprofen 5 mg/kg/day SC as necessary. Sutures are 
removed in 7–10 days postop.
Metabolic Parameters
Blood samples were collected from a tail-nick under isoflu-
rane/oxygen anesthesia, for measurement of glucose, insulin, 
and other hormones. Basal non-fasting blood samples were 
collected before treatment, at weekly intervals after treat-
ment for the first month, and at monthly intervals thereaf-
ter. Plasma samples were analyzed for insulin, glucagon, 
adiponectin, and IGF-1. Intra-peritoneal glucose tolerance 
tests were performed on successful transplant recipients at 5 
months posttransplant, in comparison with normal and dia-
betic controls. Intra-peritoneal glucose tolerance test involved 
tail-nick blood glucose measurements from 6-h fasted mice 
before (0 min) and 15, 30, 60, and 120 minutes after intraperi-
toneal injection of sterile glucose (Sigma) (1 g/kg body weight) 
under isoflurane/oxygen anesthesia.
Postmortem Tissue Collection
Mice were euthanized at different time points between 1 
and 12 months after procedure, and adipose tissue and pan-
creas were retrieved for histology. The whole pancreas and the 
adipose tissue from the subcutaneous space of the dorsal body 
surface were collected, and the tissues were preserved in 70% 
ethanol for histological analysis.
Statistical Analysis
Groups were compared 2 at a time as denoted in each 
experiment, using Students homoscedastic t test. Values are 
expressed as mean ± SEM. Numbers (n) for each group and 
statistical probabilities (P) for each comparison are specified 
in the Results section, figures, or figure legends.
RESULTS
NOD female mice develop spontaneous diabetes after 12 
weeks of age. Diabetic mice have basal non-fasting blood glu-
cose over 200 mg/dL, which quickly rises to 600 mg/dL within 
weeks. If untreated, they die or require euthanasia soon after 
the onset of diabetes. Successful BAT transplant recipients are 
defined as those diabetic mice whose basal non-fasting blood 
glucose levels decreased below 180 mg/dL and stayed below 
180 mg/dL for at least 2 months following transplant, with 
no other clinical signs of diabetes or metabolic abnormalities.
Adult BAT transplants temporarily supplemented with 
IGF-1 produced rapid and long-lasting euglycemia, similar to 
the results previously observed with embryonic BAT trans-
plants (Figure 1). Out of a total of 21 NOD mice that received 
adult BAT transplants with IGF-1 supplementation daily for 
the first week posttransplant, 12 recovered from diabetes (suc-
cessful transplants) while 9 did not (failed transplants), pro-
viding a 57% success rate. The successful transplant recipients 
achieved euglycemia within a week of treatment (Figure 1A). 
Of the successful transplant group, 9 mice remained eugly-
cemic until euthanasia at different endpoints ranging from 
6 to 12 months, while 3 reverted to diabetes at months 3 
and 7. Euglycemic transplant recipients also showed normal 
glucose tolerance comparable to normal nondiabetic con-
trols (Figure 1B). Recovery from diabetes was not generally 
observed in the control groups that received adult BAT trans-
plants alone, IGF-1 injections alone, or saline injections alone 
(Figure 1A). Due to increasing severity of clinical signs, these 
animals had to be euthanized at different time points within 
3 months from development of hyperglycemia. One mouse 
from the group treated with IGF-1 injections alone showed 
euglycemia that lasted for 3 months post procedure. This 
mouse also showed abnormalities, such as excessive weight 
gain and organ enlargement, and therefore was removed from 
the study. One mouse from the control group receiving adult 
BAT transplants alone also showed some resistance to diabe-
tes, where severe hyperglycemia did not develop immediately, 
and basal glucose levels stayed between 190 and 200 mg/dL 
for 5 weeks. While this caused an increase in the error bars in 
this group, the overall trend remained unchanged.
As previously reported with embryonic BAT transplants, 
the results are independent of insulin, as indicated by pro-
gressively decreasing levels of plasma insulin and the absence 
of insulin immunofluorescence in the pancreas postmortem 
(Figures 2A and 3). All groups show a progressive decline of 
plasma insulin as characteristic with NOD mice, compared 
with normal nondiabetic controls at 2457.4 ± 571.5 pg/mL. 
Pancreatic sections in diabetic control mice have little or 
no immuno-staining for insulin, while successful transplant 
recipients who remained euglycemic for 10 months show 
none at all (Figure 3, left panels). As diabetes progresses in 
NOD mice, there is a general decline in islet number and 
disruption of islet structure. Figure  3B and C (left panels) 
represent some of the remaining intact islets, to demonstrate 
the visible absence of insulin immunostaining. While acinar 
tissue and blood vessels can show some green autofluores-
cence, this is distinct from the actual immunofluorescence 
for insulin as seen in the control pancreas. As is characteris-
tic in NOD mice, many islets in the diabetic control group 
show immune cell infiltration and disruption of islet struc-
ture upon H&E staining (Figure 3B, Right). Such cell infil-
tration was not evident in successful transplant recipients 
(Figure 3C, Right), presumably due to a widespread decrease 
of inflammation.
Euglycemia is also accompanied by suppression of glucagon 
(Figure 2B) albeit to a lesser degree than previously observed 
with embryonic BAT transplants. Suppression of glucagon 
following transplants is further confirmed by the absence of 
glucagon immunostaining in the pancreas from successful 
transplant recipients as opposed to normal and diabetic con-
trols (Figure 3, Left panels).
Euglycemia is also associated with increases in extra-pan-
creatic insulin-mimetic hormones, which may compensate 
for the lack of insulin. Successful transplant recipients show 
consistently higher levels of plasma adiponectin and IGF-1 
compared with control groups (Figure 4). Euglycemia without 
insulin occurs only in those situations where suppression of 
glucagon is accompanied by a simultaneous increase of IGF-1 
and adiponectin. Insulin-independence is further confirmed by 
the lack of insulin-immunostaining in the transplant or sur-
rounding adipose tissue.
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Although IGF-1 is not generally expressed in WAT, eug-
lycemia following embryonic BAT transplants is associated 
with increasing expression of IGF-1 in newly formed WAT.7,8 
Similarly, current data show expression of IGF-1 in the WAT 
of successful transplant recipients who became euglycemic, 
compared with little or no expression observed in failed 
transplants and controls (Figure  5A). Again, even though 
adipocytes normally show some green autofluoresence, this 
is distinguishable from the bright immunofluorescence in 
response to the IGF-1 expression observed in successful trans-
plant recipients. IGF-1 expression in adipose tissue is observed 
only in successful transplant recipients, and some areas show 
greater expression than others. Figure 5A top left shows IGF-1 
expression over a large area at low magnification, while the 
top right image shows a brighter area of expression at higher 
magnification. While adult BAT lacks the IGF-1 expression 
normally abundant in embryonic BAT (Figure 5B), temporary 
supplementation with exogenous IGF-1 seems to enable the 
survival and function of adult BAT transplants. This leads to 
subsequent expression of IGF-1 in adipose tissue, increased 
secretion of beneficial adipokines, and insulin-independent 
glucose homeostasis.
DISCUSSION
BAT is well known to improve metabolic regulation and 
alleviate obesity, effects generally attributed to its thermogenic 
properties.12-14 However, all of its beneficial effects cannot be 
explained by thermogenesis alone, particularly considering that 
reversal of T1D following BAT transplants is associated with a 
gain of WAT rather than loss. BAT is different from WAT in its 
developmental origin as well as in function and cellular com-
position. While WAT originates from mesodermal stem cells, 
BAT originates from dermatomyotomal precursor cells as does 
skeletal muscle, and is interchangeable with skeletal muscle 
during development. Unlike WAT which stores and accumu-
lates fat, BAT is geared towards metabolism of fat and gen-
eration of heat, aided by large amounts of mitochondria and 
uncoupling protein 1. BAT shows greater vascularization and 
innervation compared with WAT, with small multilocular lipid 
droplets in brown adipocytes as opposed to the large unilocu-
lar droplets found in white adipocytes. WAT can be harmful 
under certain circumstances such as insulin-resistant obesity, 
where inflammation, hypertrophy, and necrosis of adipose tis-
sue may cause/exacerbate the metabolic dysfunction. However, 
A
B
FIGURE 1. Glucose homeostasis in NOD mice following aBAT TP supplemented with IGF-1. A, Non-fasting blood glucose levels before and 
at weekly or monthly intervals after placement of aBAT TPs followed by supplementation with IGF-1 (100 µg/kg SC) for 1 wk, in comparison with 
control groups. Successful transplant recipients (closed circles) achieve and maintain euglycemia within a wk from transplant, while the control 
groups and failed transplants (open circles) become progressively hyperglycemic. Control groups included diabetic mice treated with aBAT TPs 
alone (closed squares), IGF-1 injections alone (open squares), or saline injections alone (closed triangles). *P < 0.004 when each posttransplant 
time point of the successful transplant group is compared with corresponding time points of other groups, or their own pretransplant values. 
Normal nondiabetic controls: 132.4 ± 11.2 mg/dL. B, Intra-peritoneal glucose tolerance test in 6-h-fasted mice. n = 3 for each group *P < 0.002 
when the diabetic control group is compared with successful transplant group or normal control. aBAT TP, adult BAT transplant; BAT, brown 
adipose tissue; IGF-1, insulin like growth factor 1; NOD, non obese diabetic.
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situations where BAT and WAT functionally complement each 
other can produce great benefits including correction of meta-
bolic disease, as evidenced by the insulin-independent reversal 
of diabetes following BAT-transplants.
As demonstrated in our previous publications, euglycemia 
following embryonic BAT transplants is associated with gen-
eralized decrease of inflammation, regeneration of healthy 
WAT, suppression of glucagon, and progressive increases of 
nonpancreatic insulin-mimetic hormones primarily of adipose 
tissue origin.7,8 It is noteworthy that these results occur only 
with embryonic BAT. Adult BAT transplants or BAT-derived 
stem cell lines alone fail to produce insulin-independent eug-
lycemia, as do other embryonic tissue types. Therefore prop-
erties of both BAT and embryonic tissue seem to be critical. 
T1D is associated with inflammation of WAT and loss of 
healthy functional WAT.11,15 The thermogenicity and increased 
metabolism characteristic of BAT, and the adipogenic and 
anti-inflammatory properties unique to embryonic tissue, 
may together improve the structure and function of WAT in 
diabetic animals, enabling it to secrete beneficial adipokines 
that compensate for the lack of insulin. The inability of adult 
BAT transplants to produce euglycemia is attributable to the 
lack of such adipogenic and anti-inflammatory growth fac-
tors, which are abundantly expressed in embryonic tissue. We 
hypothesized that exogenous administration of growth fac-
tors would correct this problem. Previous data suggest IGF-1 
as a likely candidate growth factor.7
The current results confirm a critical role for IGF-1 in insu-
lin-independent euglycemia brought about by BAT transplants. 
Insulin independence is confirmed by progressively decreasing 
plasma insulin levels comparable with the diabetic controls, 
and lack of insulin immunostaining either in pancreatic islets 
or in adipose tissue. It is noteworthy that IGF-1 alone or 
adult BAT transplants alone cannot achieve euglycemia, and 
the presence of both is required. As previously observed with 
embryonic BAT transplants, adult BAT transplants temporar-
ily supplemented with IGF-1 result in rapid and long-lasting 
euglycemia in diabetic mice. Euglycemia is accompanied by 
suppression of glucagon, and increased levels of adiponectin 
and IGF-1 in plasma. The success rate in reversing diabetes is 
50%–60% in both situations. Documenting the exact reasons 
for lack of a 100% success rate is beyond the scope of this 
A
B
FIGURE 2. Changes to insulin and glucagon following aBAT TP. A, Plasma insulin levels at monthly intervals in the transplant group in 
comparison with control groups. Normal nondiabetic controls: 2457.4 ± 571.5 pg/mL. B, Plasma levels of glucagon before and at monthly 
intervals following transplant, in comparison with control groups. *P < 0.004 when the successful transplant group is compared with diabetic 
control group at the 2-mo time point. Normal nondiabetic controls: 33.6 ± 6.8 pg/mL. aBAT TP, adult BAT transplant; BAT, brown adipose tissue; 
IGF-1, insulin like growth factor 1.
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study, considering the many variables and unknowns involved 
in a treatment that works through altering the whole body 
metabolism and establishing a new physiological equilibrium. 
Variables that may be tested and adjusted in a larger scale 
study include the age of donors, time from isolation of donor 
tissue to transplantation, site of transplantation, dosage of 
IGF-1, duration of IGF-1 administration, and possible com-
bination with additional growth factors or anti-inflammatory 
agents. One consistent observation from all our experiments 
was that euglycemia occurs only when there is a simultaneous 
increase in plasma levels of IGF-1 and adiponectin together 
with suppression of glucagon. Control and failed transplant 
animals, either adult or embryonic, lack this particular hor-
monal profile, emphasizing the importance of alternate hor-
mones compensating for the lack of insulin.
The importance of these extra-pancreatic hormones in glu-
cose homeostasis is well documented. Both IGF-1 and adi-
ponectin have beneficial effects on glucose regulation, including 
some insulin independent mechanisms.43-50 Metabolic disease 
states such as diabetes, obesity, and insulin resistance are 
FIGURE 3. Pancreatic sections immuno-stained for insulin with Alexa-Fluor 488 (green), and for glucagon with Alexa-Fluor 594 (red), with 
the right column showing corresponding H&E stained sections. A, Normal nondiabetic control. B, Diabetic control treated with saline alone. C, 
Successful transplant recipient euglycemic at 10-mo .
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associated with decreased plasma levels of both hormones.51-55 
Monotherapy with IGF-1 or adiponectin are reported to alle-
viate diabetes and insulin resistance,43-50,56 even though such 
therapies are limited by side effects including hypoglycemia, 
tachycardia, edema, facial pain, or paralysis etc44,48,56 Side 
effects are unlikely with BAT transplants, since the increases in 
plasma adipokine levels are not supraphysiological, merely a 
return to normal from the decreased levels in T1D.
Recent literature shows the importance of glucagon in the 
pathogenesis of diabetes.57 The suppression of glucagon nor-
mally produced by glucose and insulin is lost in diabetes, and 
the resultant hyperglucagonemia exacerbates hyperglycemia. 
Persistent hyperglucagonemia, rather than insulin deficiency, 
has even been proposed to be the primary driver of hypergly-
cemia in diabetes. Inhibition of glucagon secretion or gluca-
gon action has been shown to restore euglycemia in diabetic 
animals, even in the absence of insulin. Thus, suppression 
of glucagon by itself is a proposed therapeutic approach for 
diabetes.57 However, pharmacological agents for direct sup-
pression glucagon secretion are not available, and glucagon 
receptor antagonists are limited by side effects and possible 
malignant transformation of α cells.58 The physiological equi-
librium produced by BAT transplants involving a combination 
of endogenous insulin-mimetic hormones and suppression of 
glucagon may well be an alternative long-term solution.
In our previous studies, streptozotocin-treated C57BL/6 
mice became euglycemic following BAT transplants, and 
showed a significant and progressive increase in leptin.8 In 
diabetic NOD recipients, we did not observe a significant 
increase of leptin, either with embryonic or adult BAT trans-
plants. Leptin may not be a major player in BAT transplant-
mediated glucose regulation, considering that BAT transplants 
A
B
FIGURE 4. Euglycemia is associated with an increase of extra-pancreatic hormones: plasma levels of IGF-1 (A) and adiponectin (B) at monthly 
intervals following transplant, in comparison with control groups. Successful transplant recipients (closed circles) show a persistent increase in 
both hormones in contrast to a decrease observed in the other groups. *P < 0.05 when the successful transplant group is compared with other 
groups at the 1 mo time point. Normal nondiabetic controls: 16.6 ± 2.5 µg/mL adiponectin and 205.4 ± 61.8 ng/mL IGF-1. aBAT TP, adult BAT 
transplant; IGF-1, insulin like growth factor 1.
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FIGURE 5. IGF-1 expression in adipose tissue: adipose tissue sections immuno-stained for IGF-1 with Alexa-Fluor 488 (green). A, NOD mice: 
IGF-1 is expressed in the adipose tissue of successful transplant recipients euglycemic at 10 mo, but not in failed transplants or controls. B, 
C57BL/6 mice: IGF-1 is expressed in freshly isolated embryonic BAT but not in adult BAT. BAT, brown adipose tissue; IGF-1, insulin like growth 
factor 1; NOD, non obese diabetic.
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are also associated with decreased inflammation, recovery of 
WAT, and a moderate weight gain.
Thus, the beneficial effects of embryonic BAT transplants 
could generally be reproduced by temporary supplementa-
tion of adult BAT transplants with exogenous IGF-1. While 
the tolerance of embryonic BAT allografts is attributable to 
the immune-privileged nature of embryonic tissue, we found 
that adult BAT transplants were also well tolerated. Literature 
shows that, unlike with other organs, rejection is not com-
mon with adipose tissue transplants.13-19 Transplanted adult 
BAT was identifiable by naked eye at 7 months posttransplant 
in some recipients, at considerably reduced size. In contrast, 
transplanted embryonic BAT soon becomes indistinguishable 
from surrounding host tissue and cannot be detected micro-
scopically.7 Development of euglycemia does not seem to 
require the presence of intact transplanted tissue, but rather, 
the positive changes imparted to the host adipose tissue such 
as decrease of inflammation, proliferation of new healthy 
WAT cells, and secretion of insulin-mimetic adipokines.7
The current results demonstrate the feasibility of establish-
ing long-term euglycemia in diabetic mice using adult BAT 
transplants, and are consistent with a model where beneficial 
insulin-mimetic hormones from adipose tissue maintain insu-
lin-independent glucose homeostasis. This effect appears to 
occur partly through glucagon suppression and partly through 
direct effects on glucose uptake and metabolism. While the 
specific underlying mechanisms remain poorly understood, we 
can make some speculations based on what has been learned 
so far. Current data suggest that donor-origin IGF-1 is essen-
tial for the survival and function of BAT transplants in the 
early stages. This possibility can be tested by deleting IGF-1 
from embryonic BAT transplants and verifying their ability 
to produce euglycemia. Successful BAT transplants establish 
a physiological equilibrium with increased adipokines and 
decreased glucagon, maintaining euglyemia in the absence of 
insulin. Preliminary data with BAT-conditioned media sug-
gest that secreted peptides from BAT transplant may suppress 
glucagon secretion from pancreatic islets and stimulate IGF-1 
secretion from liver and/or adipocytes. Studies are underway 
to identify and purify such messenger molecules.
Adult BAT transplants temporarily supplemented with 
IGF-1 is a plausible therapeutic approach transferable to 
human patients, that bypasses the complications associated 
with insulin replacement. Side effects are less likely since this 
treatment does not involve long-term administration of any 
exogenous compound, and glucose regulation is brought 
about by a physiological equilibrium of endogenous insulin-
mimetic hormones. While concerns remain regarding the 
sources and availability of donor adult BAT, possible solu-
tions include the implantation of BAT-derived stem cells or 
expansion of endogenous BAT with pharmacological agents 
such as beta-3 adrenergic agonists,59,60 together with tempo-
rary administration of IGF-1.
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